Complete tumor response in a patient with locally advanced lung large cell neuroendocrine carcinoma treated with Sintilimab plus platinum-based chemotherapy: a case report

Abstract Background pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare subset of lung cancer with a poor prognosis. As LCNEC is an uncommon malignancy, the optimal treatment for LCNEC has not been established. Case presentation : we report a case of a 66-year-old man diagnosed with unresectable, locally advanced LCNEC who presented a partial radiographic response to immunotherapy combined with chemotherapy. Salvage surgery was performed after 4 cycles of docetaxel and cisplatin (DP) regimen plus sintilimab, which is a highly selective, fully human antiprogrammed death-ligand 1 monoclonal antibody. Moreover, a pathologic analysis of the resected piece revealed the absence of residual viable tumor cells. Conclusion this case suggests that patients with locally advanced LCNEC may benefit from neoadjuvant chemo-immunotherapy, it is worthy for further study.